美國與歐盟對藥品包材可浸出物 (extractables) 與可 …

美國 FDA 於2013 年4 月發表「伸舒康 ... - cde.org.tw

RegMed 2013 Vol. 32 23 美國FDA 於2013 年4 月發表「伸舒康Samsca (Tolvaptan)藥品安全 溝通：此藥可能有肝損傷之風險，而導致器官移植或死亡，故限

www.cde.org.tw

Author: Chang, Mei-Yun\⡟㕿躖 尩 Created Date: 2/8/2018 9:42:37 AM

歐盟EMA於2012年7月提出「A型血友病患者產生抑 …

RegMed 2013 Vol. 31 3 位進行反應，進而達到生理上和藥理上的作用。除此之外，蛋白質上常常有一些轉譯後 修飾 (post-translational modifications)，例如glycoproteins，對生物製劑的療效有很大的

國際 GCP 查核制度概況 - cde.org.tw

RegMed 2016 Vol. 66 1 國際GCP 查核制度概況 陳慧容1 前言 為確保藥品臨床試驗品質與試驗結果的可信度，並保障受試者之權利、安全及福祉，

各國藥品許可證管理制度之介紹 - cde.org.tw

RegMed 2014 Vol. 41 7 各國藥品許可證管理制度之介紹 陳慧如/陳玲貴1 前言 綜觀主要醫藥管理先進國家在藥品許可證的展延制度和年報管理現況，每個

衛生福利部公告修正「西藥藥品 ... - cde.org.tw

RegMed 2017 Vol. 85 31 衛生福利部公告修正「西藥藥品優良製造規範(第一部)」部分規定，

EGFR-TKI 標靶治療藥品用於晚期及轉移性非小細胞肺癌 －療 …

RegMed 2015 Vol. 61 23 已有結果發表之LUX-lung 8 試驗及Kim et al.試驗皆是針對第二線治療進行 EGFR-TKI 療效的直接比較，兩項試驗皆未特別針對EGFR 突變進行病人篩選[註8]。其中

  Egfr

Regulatory Perspectives on Extractables and …

1 Regulatory Perspectives on Extractables and Leachables Prasad Peri, ONDQA, FDA Feb 22, 2011 PQRI Workshop on Thresholds and Best Practices for …

  Perspective, Regulatory, Extractable, Leachables, Regulatory perspectives on extractables and, Regulatory perspectives on extractables and leachables

Thresholds and Best Practices for Extractable and …

Overview of Thresholds and Best Practices for Extractable and Leachables(L&E) 3rd PQRI/FDA Conference on Advancing Product Quality Washington DC, 22 …

  Practices, Practices for extractable and, Extractable, Practices for extractable and leachables, Leachables

MDI VALVES AND ACTUATORS - Bespak

• The valve is the most technically complex element in an MDI, and critical to delivering a consistent and precise metered dose of medication to users

  Valves, Actuator, Mdi valves and actuators

Guideline on Inhalational medicinal products

emea/chmp/qwp/49313/2005 corr emea 2006 page 2/27 guideline on the pharmaceutical quality of inhalation and nasal products table of contents

  Guidelines, Guideline on

Regulatory Considerations for Peptide Drug Products

Regulatory Considerations for Peptide Drug Products Larisa C. Wu Peptide Team OGD/CDER/FDA 2013 GPhA/FDA CMC Workshop June 5, 2013 This presentation reflects the views of the author and

  Product, Drug, Regulatory, Considerations, Peptides, Regulatory considerations for peptide drug products

Extractables, Leachables & Elemental Impurities-West

Register Now to Guarantee Your Space! Online: www.pharmaedresources.com • Phone: 21.21.5 Extractables, Leachables, and Elemental Impurities 2017 West Coast

  Impurities, Elemental, Extractable, Leachables, Leachables amp elemental impurities

Extractables, Leachables, & Elemental Impurities …

Register Now to Guarantee our Space! Online: wwwpharmaedresourcescom hone: 217.721.5774 Extractables, Leachables, & Elemental Impurities 2018 West Coast

  Leachables